XML 62 R51.htm IDEA: XBRL DOCUMENT
v3.21.2

Royalty Purchase Agreements - Agenus (Details) $ in Thousands |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Sep. 20, 2018 USD ($) product | Nov. 30, 2020 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2020 USD ($) | Dec. 31, 2020 USD ($)
Agreements |  |  |  |  |  |  |
Payments to acquire milestones and royalties |  |  |  |  | $ 20,500 |  |
Long-term royalty receivables |  |  | $ 55,075 |  | 55,075 |  | $ 34,575
Revenue from contracts with customers |  |  | $ 550 | $ 200 | 1,094 | $ 753 |
Impairment of long-term royalty receivable |  |  |  |  | 0 |  | $ 0
Royalty Purchase Agreement [Member] | Merck Immuno-Oncology Product | Agenus [Member] |  |  |  |  |  |  |
Agreements |  |  |  |  |  |  |
Amount of milestone achieved |  | $ 10,000 |  |  |  |  |
Agenus [Member] | Royalty Purchase Agreement [Member] |  |  |  |  |  |  |
Agreements |  |  |  |  |  |  |
Payments to acquire milestones and royalties | $ 15,000 |  |  |  |  |  |
Long-term royalty receivables | 15,000 |  |  |  |  |  |
Impairment of long-term royalty receivable |  |  |  |  | $ 0 |  |
Agenus [Member] | Royalty Purchase Agreement [Member] | Silicon Valley Bank [Member] |  |  |  |  |  |  |
Agreements |  |  |  |  |  |  |
Proceeds from issuance of long-term debt | $ 7,500 |  |  |  |  |  |
Agenus [Member] | Royalty Purchase Agreement [Member] | Incyte Immuno-Oncology Assets |  |  |  |  |  |  |
Agreements |  |  |  |  |  |  |
Royalties entity has right to receive (as a percent) | 33.00% |  |  |  |  |  |
Number of licensed products related to milestone and royalties | product | 6 |  |  |  |  |  |
Purchased percentage of milestones | 10.00% |  |  |  |  |  |
Agenus [Member] | Royalty Purchase Agreement [Member] | Merck Immuno-Oncology Product |  |  |  |  |  |  |
Agreements |  |  |  |  |  |  |
Royalties entity has right to receive (as a percent) | 33.00% |  |  |  |  |  |
Purchased percentage of milestones | 10.00% |  |  |  |  |  |
Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones | $ 59,500 |  |  |  |  |  |
Amount of milestone achieved |  | 1,000 |  |  |  |  |
Cash receipts for achievement of contractual milestones |  | $ 1,000 |  |  |  |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfLongTermDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash receipts for achievement of contractual milestones. + References No definition available. + Details
Name: | xoma_CashReceivedForAchievementOfContractualMilestones
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets. + References No definition available. + Details
Name: | xoma_ImpairmentOfLongTermRoyaltyReceivable
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Long-term royalty receivable non current. + References No definition available. + Details
Name: | xoma_LongTermRoyaltyReceivableNonCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of milestone achieved. + References No definition available. + Details
Name: | xoma_MilestoneAchieved
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of licensed products related to milestones and royalties purchased. + References No definition available. + Details
Name: | xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payments related to purchase of royalty rights. + References No definition available. + Details
Name: | xoma_PaymentsRelatedToPurchaseOfRoyaltyRights
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones. + References No definition available. + Details
Name: | xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Purchased percentage of milestones. + References No definition available. + Details
Name: | xoma_PurchasedPercentageOfMilestones
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Royalties entity has the right to receive as a percentage. + References No definition available. + Details
Name: | xoma_RoyaltyReceivablePercentageOnNetSales
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_MerckImmunoOncologyProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=xoma_AgenusIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_AgenusIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_IncyteImmunoOncologyAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |